Business Context and Reporting Period
Company: GridAI Technologies Corp. (GRDX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: The Company operates two segments: a legacy gastrointestinal (GI) biopharmaceutical business (focused on Adrulipase) and an AI-driven energy technology business (Grid AI Corp.) acquired in September 2025. The Company previously rescinded its acquisition of ImmunogenX (IMGX) in December 2025.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value |
|---|---|
| Revenue | $124,084 |
| Net Loss | $(16,478,995) |
| Net Loss Attributable to Common Shareholders | $(16,307,455) |
| Loss Per Share (Basic & Diluted) | $(2.81) |
| Cash and Cash Equivalents (Ending) | $1,379,721 |
| Working Capital Deficit | ~$(11.8 million) |
| Total Debt (Current) | ~$7.9 million (Includes $6.25M deferred consideration) |
| Accumulated Deficit | $(224.9 million) |
Material Changes vs. Prior Period
- Revenue: Increased from $0 in the prior year period to $124,084, driven entirely by the new AI Segment. The legacy GI Segment generated no revenue.
- Goodwill Impairment: Recognized a non-cash impairment charge of $10.07 million due to delays in commercialization and customer contract execution for the Grid AI business. No impairment was recorded in the prior year.
- Operating Expenses: Total operating expenses increased significantly to $16.07 million from $1.46 million in the prior year, primarily due to the integration of Grid AI, increased professional fees, and the goodwill impairment charge.
- Discontinued Operations: The prior year included a loss from discontinued operations of $634,855 related to the IMGX business, which was fully rescinded and derecognized by December 31, 2025.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for one year from the date of issuance due to a working capital deficit and accumulated losses. Continued operations depend on raising additional capital.
- Commercialization Delays: The goodwill impairment reflects delays in the AI Segment's revenue ramp-up. Management maintains long-term confidence but acknowledges uncertainty in near-term cash flows.
- Financing Activity: The Company raised approximately $7.8 million in May 2026 private placements and entered into a new $8.5 million financing agreement in July 2026 (subsequent event). It also settled a defaulted revolving loan in May 2026 via cash and stock issuance.
- Legal Proceedings:
- WestPark Capital: Arbitration pending; Company accrued $202,000 against a claim of ~$2.06 million.
- Asymchem Inc. Judgment of ~$209,000 entered; payment stipulation reached in August 2026.
- EGS: Legal fee dispute settled for $360,000 in May 2026.
- Internal Controls: Disclosure controls and procedures were deemed ineffective due to a material weakness related to the integration of Grid AI Corp.
Investor Verification Checklist
- Liquidity Runway: Verify the status of the July 2026 financing closing and the collection of the remaining 80% of May 2026 proceeds contingent on registration statement effectiveness.
- Goodwill Impairment Drivers: Review specific details on the "delays in commercialization" cited for the $10.1M impairment to assess if further impairments are likely.
- Debt Obligations: Confirm the repayment schedule for the $6.25 million deferred consideration and the $1.68 million in notes payable.
- Legal Accruals: Monitor the outcome of the WestPark arbitration, as the accrued $202,000 may be insufficient if the full claim is upheld.
- Going Concern Mitigation: Assess the feasibility of the Company's plan to raise capital given the current market conditions and Nasdaq compliance history.